165 related articles for article (PubMed ID: 32208602)
1. Metal-Labeled Aptamers as Novel Nanoprobes for Imaging Mass Cytometry Analysis.
Yu Y; Dang J; Liu X; Wang L; Li S; Zhang T; Ding X
Anal Chem; 2020 May; 92(9):6312-6320. PubMed ID: 32208602
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
3. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
5. Aptamer Probes Labeled with Lanthanide-Doped Carbon Nanodots Permit Dual-Modal Fluorescence and Mass Cytometric Imaging.
Yu Y; Wang X; Jia X; Feng Z; Zhang L; Li H; He J; Shen G; Ding X
Adv Sci (Weinh); 2021 Dec; 8(24):e2102812. PubMed ID: 34719883
[TBL] [Abstract][Full Text] [Related]
6. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
7. The use of aptamers in prostate cancer: A systematic review of theranostic applications.
Campos-Fernández E; Oliveira Alqualo N; Moura Garcia LC; Coutinho Horácio Alves C; Ferreira Arantes Vieira TD; Caixeta Moreira D; Alonso-Goulart V
Clin Biochem; 2021 Jul; 93():9-25. PubMed ID: 33794195
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Lupold SE; Hicke BJ; Lin Y; Coffey DS
Cancer Res; 2002 Jul; 62(14):4029-33. PubMed ID: 12124337
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
Min K; Song KM; Cho M; Chun YS; Shim YB; Ku JK; Ban C
Chem Commun (Camb); 2010 Aug; 46(30):5566-8. PubMed ID: 20407731
[TBL] [Abstract][Full Text] [Related]
10. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
[TBL] [Abstract][Full Text] [Related]
12. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Kim D; Jeong YY; Jon S
ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
[TBL] [Abstract][Full Text] [Related]
13. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
15. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.
Rockey WM; Hernandez FJ; Huang SY; Cao S; Howell CA; Thomas GS; Liu XY; Lapteva N; Spencer DM; McNamara JO; Zou X; Chen SJ; Giangrande PH
Nucleic Acid Ther; 2011 Oct; 21(5):299-314. PubMed ID: 22004414
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
17. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
18. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
[TBL] [Abstract][Full Text] [Related]
20. [Domestication of suspension CHO cells and its application in the expression of anti-PSMA antibody].
Wu J; Han D; Wei M; Zheng G; Jiao D; Xi W; Yang A; Qin W; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jan; 32(1):1-4. PubMed ID: 27358992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
